Saturday, 5 September 2026European Markets

BELIEVE Stock Impressive Rise On Tuesday, Outperforms Market

Loading stream...

(vianews) - the market ended the session with believe (blv.pa) rising 18.39% to €14.68 on tuesday while cac 40 slid 0.84% to €7,625.31.

believe's last close was €12.40, 2.82% below its 52-week high of €12.76.

about believe

believe s.a. provides music distribution and marketing services for artists and labels worldwide. the company's physical and digital distribution services include a range of digital music services and video streaming, as well as a network of physical distribution partners. it also provides brand partnership, video, synchronization, music publishing and additional services. believe s.a. was incorporated in 2005 and is headquartered in paris, france.

earnings per share

as for profitability, believe has a trailing twelve months eps of €-0.22.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.27%.

sales growth

believe's sales growth is 32.3% for the ongoing quarter and 14.3% for the next.

moving average

believe's worth is way above its 50-day moving average of €10.55 and way higher than its 200-day moving average of €10.24.

more news about believe (blv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com